摘要
目的:探讨帕利哌酮缓释片治疗老年精神分裂症的疗效和安全性。方法:将60例老年精神分裂症患者随机分为研究组和对照组,各30例,分别给予帕利哌酮缓释片(芮达)与奥氮平片(再普乐)治疗,疗程8周,分别于治疗前、治疗第2周、第4周和第8周末采用阳性与阴性症状量表(PANSS)评定疗效;用治疗中出现的症状量表(TESS)来评定不良反应。结果:两组PAN-SS量表评分治疗后均较治疗前明显减少(P<0.05);研究组显效率和有效率分别为56.7%和76.7%,对照组分别为53.3%和73.3%,差异无统计学意义(P>0.05);帕利哌酮缓释片的主要不良反应为锥体外系副反应,奥氮平片主要不良反应为嗜睡和体质量增加,两组差异有统计学意义(P<0.05)。结论:帕利哌酮缓释片对治疗老年精神分裂症患者有较高的疗效和安全性。
Objective：To investigate the efficacy and safety of the Pali- peridone extended-release tablets and olanzapine in treating elderly schizophrenia. Methods： 60 patients with elderly schizophrenia were randomly divided into study group and control group, 30 cases were given Paliperidone extended-release tablets and olanzapine treatment daily for 8 weeks, respectively, before treatment, 2 weeks, 4 weeks and 8 weeks using the Positive and Negative Syndrome Scale （PANSS） to evaluate the efficacy; Treatment Emergent Symptom Scale （TESS） to assess the adverse reactions. Results： The PANSS score of two groups were significantly reduced after treat- ment than before （ P 〈 0. 05 ）. The efficient and effective rates of Study group were 56. 7% and 76. 7% in the control group were 53.3% and 73.3%. There were no significant differences （ P 〉 O. 05 ）. The major adverse events of palisperidone extended-release tab- lets were extrapyramidal department of side effects, the major adverse effects of olanzapine increased lethargy and body mass, There were significant difference （ P 〈 0. 05 ）. Conclusion： Palisperidone extended-release tablets for the treatment of elderly patients with schizophrenia have a higher efficacy and safety.
出处
《中国药物滥用防治杂志》
CAS
2013年第2期93-95,共3页
Chinese Journal of Drug Abuse Prevention and Treatment
关键词
帕利哌酮缓释片
奥氮平片
老年
精神分裂症
Paliperridone extened-release table
Olanzapine tablets
Elderly
Schizophrenia
